Servier Pharmaceuticals · 17 hours ago
Advanced Analytics Intern - Solid Tumors
Boston, MA
Internship
Hybrid
Intern
$24/hr - $24/hrServier Pharmaceuticals is a Boston-based biopharmaceutical company focused on advancing science and patient care. The Advanced Analytics Intern will support the Corporate Strategy Development & Operations team by contributing to data-driven projects and developing marketing dashboards using Google Cloud Platform and Power BI.
Health CareMedicalPharmaceutical
Responsibilities
Develop a new marketing dashboard, utilizing diverse data sets in the Google Cloud Platform environment
Collaborate cross-functionally with Marketing Team to understand and support data needs
Develop ad hoc and deep dive analytics using technical skills to answer stakeholder questions
Contribute to the execution of complex analytical projects with cross-functional impact
Qualification
Required
BS/BA degree candidate in business, science, or quantitative disciplines such as mathematics, engineering, or statistics
Strong understanding of SQL
Strong analytical and problem-solving abilities
Effective written and verbal communication skills
Ability to work collaboratively in a team
Strong interpersonal skills and ability to build working relationships
Curiosity and a proactive mindset
Discretion when handling sensitive or confidential information
Adaptability in a fast-paced environment
Preferred
Experience with business intelligence software, such as Power BI or Tableau
Company
Servier Pharmaceuticals
Servier Pharmaceuticals is a pharmaceutical company dedicated to therapeutic progress to serve patient needs.
Founded in 2018
201-500 employees
H1B Sponsorship
Servier Pharmaceuticals has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (2)
2024 (4)
2023 (4)
2022 (3)
2021 (15)
2020 (2)
Funding
Current Stage
Growth StageLeadership Team
David K. Lee
Chief Executive Officer
Pedro Crisanto
Chief Operating Officer R&D, USA
Recent News
2025-12-08
Company data provided by crunchbase